DOCSLIB.ORG

Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013 Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE 22280-60-0 6-Chloro-2-methyl-3-nitropyridine 68301-59-7 2'-Chloro-4'-hydroxyacetophenone 159290-96-7 3-PYRIDINEMETHANESULFONYLCHLORIDE 17573-78-3 4,5,6-TRIFLUOROPYRIMIDINE 67341-01-9 N-BOC-D/L-PHENYLGLYCINOL 19745-07-4 2,5-Dichloropyrazine 127232-42-2 5-(BROMOMETHYL)OXAZOLE 27407-11-0 3-Bromo-4-fluorophenol 5304-21-2 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE 53055-05-3 3-Methoxy-2-nitrobenzaldehyde 22996-21-0 4-METHOXY-2-NITRO-BENZALDEHYDE 205318-52-1 3-(AMINOMETHYL)-1-N-BOC-ANILINE 2901-13-5 Ethyl2,2-dimethylphenylacetate 13094-51-4 BROMOACETICANHYDRIDE 13512-57-7 BOC-ASN-OBZL 20781-23-1 BIS(2,4-DIMETHOXYBENZYL)AMINE 871329-51-0 3-AMINO-5-NITROBENZENEBORONICACIDPINACOLESTER 70-25-7 1-Methyl-3-nitro-1-nitrosoguanidine 4385-35-7 3-ISOCHROMANONE 13382-54-2 2-CHLORO-6-PHENYLPYRIDINE 29289-13-2 2-IODO-4-METHYLANILINE 10242-01-0 5-Methoxy-3-indolecarboxylicacid 272-49-1 4-Azaindole 126085-91-4 ETHYL5-TRIBUTYLSTANNANYLISOXAZOLE-3-CARBOXYLATE 130025-33-1 5-CHLORO-2,4-DIFLUOROBENZOICACID 173435-41-1 3-AMINO-2-CHLORO-ISONICOTINICACIDMETHYLESTER 22536-62-5 2-CHLORO-5-PHENYL-PYRIMIDINE 127108-66-1 1,2,3-Thiadiazole-5-carboxaldehyde,4-methyl-(9CI) 163008-98-8 4-(CHLOROMETHYL)-1H-PYRAZOLEHYDROCHLORIDE 101711-78-8 (4S)-(+)-4-Benzyl-3-propionyl-2-oxazolidinone 23842-82-2 2-Amino-5-methoxybenzonitrile 72721-02-9 5,6-Dimethoxybenzimidazole 3770-50-1 Ethylindole-2-carboxylate 157688-46-5 1-Boc-4-piperidylaceticacid 252049-10-8 FMOC-LYS(ME)2-OHHCL 201004-29-7 FMOC-LYS(ME3)-OHHCL 220127-57-1 Imatinibmesylate 16732-70-0 2-(Ethoxycarbonyl)-5-bromo-indole 55379-96-9 3-(4-BUTOXYPHENYL)-2-PROPENOICACID 14521-80-3 3-BROMO-1H-PYRAZOLE 169590-42-5 Celecoxib 118276-06-5 3,5-Difluoro-4-hydroxybenzaldehyde 57044-25-4 (R)-(+)-Glycidol 32864-38-3 TERT-BUTYLETHYLMALONATE 88301-98-8 2-Methyl-6-(trifluoromethyl)aniline 80-70-6 Tetramethylguanidine 38418-24-5 N-(4-BROMO-PHENYL)-3-OXO-BUTYRAMIDE 22532-62-3 4-Bromo-2-hydroxybenzaldehyde 25235-85-2 4-Chloroindole 104530-79-2 (S)-3-AMINOTETRAHYDROFURAN 4221-03-8 5-HYDROXYPENTANAL 4752-10-7 1,4-Dichlorophthalazine 920-37-6 2-Chloroacrylonitrile 125078-15-1 (1-AMINO-2,2-DIMETHYLPROPYL)PHOSPHONICACIDHYDRATE 28620-12-4 6-Nitro-2-benzothiazolinone 39884-48-5 4-AMINO-2-BUTANOL 2867-59-6 3-AMINO-BUTAN-1-OL 2183-66-6 2-(METHYLTHIO)PYRIMIDIN-4-AMINE 13036-57-2 2-Chloro-4-methylpyrimidine 25168-73-4 Sucrosestearate 84249-14-9 2-Amino-4-bromopyridine 3145-76-4 1-METHYL-2-PHENYLCYCLOPROPANE 6526-08-5 2-Amino-5-trifluoromethylbenzonitrile 181513-29-1 6-(Trifluoromethyl)indoline 1526-17-6 2-Fluoro-6-nitrophenol 1722-62-9 Mepivacainehydrochloride 29241-60-9 2-Chloro-3-methyl-5-bromopyridine 147291-66-5 tert-Butyl3-aminobenzylcarbamate 5779-93-1 2,3-Dimethylbenzaldehyde 22041-19-6 ETHYLPYRROLIDINOACETATE 654663-32-8 3-METHOXY-4-PYRIDINECARBOXYLICACID 1006-64-0 2-Phenylpyrrolidine 60093-05-2 4-AMINO-2-METHYLTHIO-5-THIAZOLECARBOXYLICACIDMETHYLESTER 50534-49-1 3-DIMETHYLAMINOPIPERIDINE 207346-42-7 Methyl2-amino-4,5-difluorobenzoate 32536-52-0 OCTABROMODIPHENYLETHER 27048-04-0 2-Amino-6-chloro-3-nitropyridine 3469-69-0 4-Iodopyrazole 103745-39-7 FASUDIL 146539-83-5 2-METHOXY-5-(TRIFLUOROMETHYL)BENZALDEHYDE 103040-78-4 4-AMINO-7-METHOXYLQUINOLINE 69411-67-2 2-Fluoro-4-nitrobenzotrifluoride 492-38-6 Atropicacid 17809-36-8 2-FLUORO-6-NITRO-PHENYLAMINE 10318-18-0 DL-Cysteinehydrochloride 621-84-1 Benzylcarbamate 3920-50-1 Pyrazol-3-carbaldehyde 446-31-1 4-AMINO-2-FLUOROBENZOICACID 89499-43-4 4-AMINO-THIOPHENE-2-CARBOXYLICACIDMETHYLESTER 5500-21-0 Cyclopropanecarbonitrile 25843-45-2 AZOXYMETHANE 129938-20-1 Dapoxetinehydrochloride 171596-29-5 Cialis 29684-56-8 Burgessreagent 29767-20-2 Teniposide 87893-55-8 15D-PGJ2 59894-07-4 13,14-DIHYDRO-15-KETOPROSTAGLANDIND2 13192-04-6 Dimethyl2-oxoglutarate 1011-37-6 5-(CHLOROMETHYL)-3-PHENYLISOXAZOLE 77820-58-7 Methyl2-amino-3-chlorobenzoate 5604-46-6 2-Amino-4,6-dichloro-5-formylpyrimidine 7556-47-0 6-METHOXY-2,3-DIHYDRO-1H-INDOLE 1750-42-1 3-Aminoisoxazole 52-53-9 Verapamil 2368-80-1 2-Fluorophenylhydrazine 591-55-9 5-AMINOPYRIMIDINE 39061-97-7 4-Chloro-3-nitroquinoline 244221-57-6 5-CHLORO-2-IODOPYRIDINE 23056-33-9 2-Chloro-4-methyl-5-nitropyridine 161661-17-2 (R)-8-BROMO-2-AMINOTETRALIN 82409-18-5 4-HYDROXYTETRAHYDROISOXAZOL-2-IUMCHLORIDE 52320-59-9 5-ETHYL-ISOXAZOLE-3-CARBOXYLICACID 5347-68-2 2,3-DIMETHYLPIPERIDINE 276872-90-3 1-OXA-5-AZASPIRO[2.5]OCTANE-5-CARBOXYLICACID,1,1- DIMETHYLETHYLESTER 475275-69-5 (5-CHLORO-2-METHOXYPYRIDIN-4-YL)BORONICACID 885277-67-8 3-(2-Chloro-Phenyl)-Pyrrolidine 40155-28-0 2-CHLORO-3-METHOXYPYRAZINE 856171-16-9 2-Chloro-6-(1-methylethyl)benzothiazole 539-23-1 5-AMINO-2-BUTOXYPYRIDINE 956-90-1 PHENCYCLIDINEHYDROCHLORIDE 19752-57-9 1,3-DIBROMO-5-IODOBENZENE 86-59-9 8-Quinolinecarboxylicacid 71-43-2 Benzene 73033-58-6 5-CHLORO-2-NITROBENZYLALCOHOL 88675-24-5 3-FURANAMINE,TETRAHYDRO- 10147-40-7 1-DODECANESULFONYLCHLORIDE 1120-87-2 3-IODOPYRIDINE 2240-25-7 6-AMINO-5-BROMOPYRIMIDIN-2(1H)-ONE 96-42-4 3-Pyrrolidinone 3400-55-3 2-BROMOPRIOPIONALDEHYDEDIETHYLACETAL 16096-32-5 4-Methylindole 15861-36-6 6-Cyanoindole 96107-94-7 1H-TETRAZOLE-5-CARBOXYLICACIDETHYLESTERSODIUMSALT 7150-12-1 2,2-DIPHENYL-CYCLOPROPANECARBOXYLICACID 116861-31-5 N-BOC-3-CHLOROPROPYLAMINE 21962-47-0 2-CYANO-4-METHOXYBENZALDEHYDE 3810-80-8 DIPHENOXYLATEHYDROCHLORIDE 3828-49-7 2,3-Difluorotoluene 261903-03-1 2-BROMO-4-IODOBENZALDEHYDE 73536-69-3 Bifendatatum 26386-88-9 Diphenylphosphorylazide 1405-86-3 Glycyrrhizicacid 2941-29-9 CYCLOPENTANONE-2-CARBONITRILE 1979-98-2 2-Methylthio-4,6-pyrimidinedione 5447-02-9 3,4-Dibenzyloxybenzaldehyde 56133-86-9 2,5-DICHLOROPHENETHYLAMINE 27527-05-5 L-Cyclohexylalanine 4487-50-7 4-NITRO-PYRIDIN-2-YLAMINE 16837-52-8 Ammothamnine 135654-16-9 3-(CHLOROMETHYL)BENZAMIDE 24552-27-0 3-CHLOROPROPIONICACIDPHENYLESTER 151-56-4 Ethyleneimine 507-52-8 2-TRIFLUOROMETHYL-2-PROPANOL 338-83-0 Perfluorotripropylamine 1691-99-2 N-Ethyl-N-(2-hydroxyethyl)perfluorooctylsulphonamide 400-93-1 4'-Fluoro-3'-nitroacetophenone 31786-45-5 2-BROMO-6-METHOXYBENZOICACID 14916-64-4 2-NITRO-PYRIDIN-4-YLAMINE 99365-40-9 6-Bromo-1,3-dihydro-2H-indol-2-one 55404-31-4 3-BROMO-2-CHLORO-4-PICOLINE 155976-13-9 Boc-L-cyclopropylglycine 26377-17-3 ETHYLISONICOTINOYLACETATE 79-83-4 D-PANTOTHENICACID 4123-72-2 4-Amino-3,5-dibromobenzoicacid 635-90-5 1-PHENYLPYRROLE 16096-33-6 1-PHENYL-1H-INDOLE 53780-44-2 3-Chloro-4,5-difluoronitrobenzene 99433-28-0 2-BROMO-1-(4-CYCLOHEXYLPHENYL)ETHANONE 747392-34-3 2-Bromo-5-fluorobenzylamine 66225-51-2 3-ETHYL-1-PENTANOL 76-41-5 OXYMORPHONE 922-68-9 Methyl2-oxoacetate 197638-83-8 1-BOC-4-(4-FORMYLPHENYL)PIPERAZINE 15568-85-1 5-(METHOXYMETHYLENE)-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE 4472-44-0 2-Chloro-4,6-dimethylpyrimidine 3987-92-6 METHYL4-AMINO-3-NITROBENZOATE 18282-51-4 4-Iodobenzylalcohol 16644-30-7 3-CHLOROMETHYL-5-NITROSALICYLALDEHYDE 167081-25-6 TERT-BUTYLCIS-4-HYDROXYCYCLOHEXYLCARBAMATE 849928-26-3 1-N-BOC-3-BROMOPIPERIDINE 86-68-0 QUININICACID 998-93-6 4-BROMOHEPTANE 100564-78-1 Boc-L-homophenylalanine 82702-31-6 3-BROMO-4-FLUORO-BENZOICACIDMETHYLESTER 817186-93-9 4-(4-CHLOROPHENOXY)PIPERIDINEHYDROCHLORIDE 6257-03-0 2,3,5,6-TETRAFLUORONITROBENZENE 73583-41-2 4-Bromo-3-chloropyridine 33332-29-5 2-Amino-5-chloropyrazine 74553-29-0 2,5-Dibromobenzaldehyde 16820-12-5 5-Ethyl-5-methylhydantoin 13505-06-1 3-HYDROXY-4-NITROPYRIDINE 35970-34-4 2-BROMO-1-(3,4-DIHYDRO-2H-1,5-BENZODIOXEPIN-7-YL)ETHAN-1-ONE 7461-50-9 4-Amino-2-chloropyrimidine 4175-66-0 2,5-Dimethylthiazole 136-90-3 4-AMINO-2-METHYLANISOLE 612-17-9 1,4-DIHYDRONAPHTHALENE 59664-42-5 2,4-BIS(TRIFLUOROMETHYL)BENZALDEHYDE 999-06-4 4-BROMOOCTANE 99011-02-6 Imiquimod 63910-43-0 4-CHLORO-5-METHOXYPYRIDAZIN-3(2H)-ONE 71322-99-1 2-Methyl-4-piperidone 18614-46-5 2-FLUORO-4-NITROPYRIDINE 1787-44-6 METHYL-D3-TRIPHENYLPHOSPHONIUMBROMIDE 35320-22-0 D-Alaninamide 70639-78-0 2-(1H)-QUINOLINENE-6-CARBOXYLICACID 3952-42-9 9-N-BUTYLFLUORENE 1572-46-9 9-BENZYLFLUORENE 3272-08-0 4-Hydroxy-3-nitrobenzonitrile 6048-21-1 4-BROMOBENZOYLCYANIDE 475058-41-4 (S)-3-Hydroxypiperidinehydrochloride
Load more

Recommended publications
  • Prezentace Aplikace Powerpoint
    Analgesics - antipyretics = „weak“ analgesics = non-opioid analgesics Most of them also • non-steroidal anti-inflamatory drugs (NSAIDs) •antirheumatics Oldřich Farsa 2011 Metabolism of eicosanoids O O arachidonic O H acid = 2 C O R1 R2 OH R2 O OH CH C O P O + 3 H N CH 2 O 3 CH3 glucocorticoids inhibitors of phspholipase A2 prostaglandins sythesis = COOH = "weak" analgesics + lipoxygenase inhibitors + NSAIDs arachidonic acid cyclooxygenases (COX1 + COX2) lipoxygenase OOH O COOH COOH O PG 5-hydroperoxy-6-trans-8,11,14-cis-eikosatetraenoic acid G2 OOH (5-HPETE) cyklooxygenases tromboxan synthase prostacyklin synthase PG H2 PG I2 = prostacyklin TX A2 endothelium cells LT A4 trombocytes isomerases PG D2 PG E2 LT C4 LT B4 PG F2α all the cells LT D4 LT E4 Effects of prostaglandins ↓ Prostaglandin E, F2α : ache, fewer, inflammation, sekretion of HCl , stomach mucosa capilaries dilatation, contraction of + ↑ uterus, kidneys: excretion of Na and H2O Prostacyclin (prostaglandin I ): vasodilatation, platelets aggregation inhibition 2 Tromboxan: vasokonstriction, platelets aggregation activation Leukotriens: alergic reactions (e.g. asthma bronchiale) Cyklooxygenases (= prostaglandin G/H synthases) COX1 Constitutive: in all the tissues Functions: •protection of stomach mucosa (vasodilatation) •diuresis •platelets aggregation (TXA) COX2 Philipp Needlemann Constitutive: kidneys, brain (co-localized with cyclins D and E) inventor of COX 1 isoenzymes Inducible: macrophages, neutrophfils, fibroblasts, endothelium cells (1989) Functions: •vasodilatation
    [Show full text]
  • Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information
    Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity
    [Show full text]
  • Buffered Mag Glycinate W L-Taurine P.Pub
    Magnesium BisGlycinate TM buffered w/L-Taurine 90 Veggie Capsules NPN80026983 Matrix Nutritional Series Cardiac, Neurological & Musculo-Skeletal Support Matrix Nutritionals Series was designed as an eclectic offering for the Physica Energetics line of remedies primarily to assist in the “reactivation of the mesenchyme” (Dr. Reinhold Voll), via the nutritional complement pathways. These pathways are present in every system throughout the body and require balanced attention. In keeping with the principles of BioEnergetic Medicine, the remedies nourish and support these systems without punishing them with overstimulation or imbalancing factors, which, ultimately, is counterproductive. This approach has been carefully and respectfully designed to provide the necessary natural (organic where available), synergistic factors in proper energetic and biochemical ratios, to ensure assistance towards yielding a deep and lasting result. They are not to be confused with replacement therapy nutraceuticals that may seem to help for the moment, until the patient stops taking them or the condition is driven deeper. These remedies honour The Legacy of BioEnergetic Medicine, and are known by both patient and practitioner to be exceptionally effective. In 2006, the World Health Organization reached consensus experience twitches (in the eyelids as well!), cramps, muscle that a majority of the world's population is magnesium tension, muscle soreness, including back aches, neck pain, deficient. Likewise, in 1995, the Gallop Organization conducted a tension headaches and jaw joint (or TMJ) dysfunction. Also, one survey and found that 95% of adult Americans are magnesium may experience chest tightness or a peculiar sensation that one deficient! can't take a deep breath. Sometimes a person may sigh a lot.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Lurasidone in Combination with Lithium Or Valproate for the Maintenance Treatment of Bipolar I Disorder$
    European Neuropsychopharmacology (]]]]) ], ]]]–]]] www.elsevier.com/locate/euroneuro Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder$ Joseph R. Calabresea, Andrei Pikalovb,c, Caroline Streicherb,c, Josephine Cucchiarob,c, Yongcai Maob,c, Antony Loebelb,c,n aUniversity Hospitals Case Medical Center, Case Western Reserve University, Cleveland, United States bSunovion Pharmaceuticals Inc., Marlborough, MA, United States cSunovion Pharmaceuticals Inc., Fort Lee, NJ, United States Received 15 November 2016; received in revised form 7 June 2017; accepted 20 June 2017 KEYWORDS Abstract Bipolar disorder; Lurasidone (DS-RAn) has demonstrated efficacy in the acute treatment of bipolar depression, Recurrence; both as monotherapy, and as combination therapy with lithium or valproate. To evaluate the Atypical antipsycho- recurrence prevention efficacy of lurasidone for the maintenance treatment of bipolar I tic; disorder, patients received up to 20 weeks of open-label lurasidone (20–80 mg/d) combined Lurasidone with lithium or valproate during an initial stabilization phase. A total of 496 patients met stabilization criteria and were randomized to 28 weeks of double-blind treatment with lurasidone (20–80 mg/d) or placebo, in combination with lithium or valproate. Based on a Cox proportional hazard model, treatment with lurasidone reduced the probability of recurrence of any mood episode by 29% (primary endpoint), however, the reduction did not achieve statistical significance. Probability of recurrence on lurasidone was significantly lower in patients with an index episode of depression (HR, 0.57; P=0.039), in patients with any index episode who were not rapid-cycling (HR, 0.69; P=0.046), and when recurrence was based on MADRS, YMRS, or CGI-BP-S severity criteria (HR, 0.53; P=0.025; sensitivity analysis).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto Et Al
    US 20090156582A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto et al. (43) Pub. Date: Jun. 18, 2009 (54) PYRAZOLE COMPOUND Publication Classification (76) Inventors: Tetsuya Tsukamoto, Osaka-shi, (51) Int. Cl. Osaka (JP); Takeshi Yamamoto, A6II 3/55 (2006.01) Osaka-shi,Osaka (JP); Ryosuke A63L/454 (2006.01) Tokunoh, Osaka-shi, Osaka (JP); A63L/462 (2006.01) Tomohiro Kawamoto, Osaka-shi, C07D 403/02 (2006.01) Osaka (JP); Masahiro Okura, Osaka-shi, Osaka (JP); Masakumi (52) U.S. Cl. .................... 514/217.09: 514/406; 514/326; Kori, Osaka-shi, Osaka (JP); 548/364.1: 548/368.4: 546/211; 540/603 Katsuhito Murase, Osaka-shi, Osaka (JP) (57) ABSTRACT Correspondence Address: The present invention provides a pyrazole compound repre WENDEROTH, LIND & PONACK, L.L.P. sented by the formula (I): 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503 (US) b (Io) (21) Appl. No.: 11/884,054 Ra R (22) PCT Filed: Feb. 9, 2006 (86). PCT No.: PCT/UP2006/302686 S371 (c)(1), wherein ring Ao is a pyrazole ring optionally further having 1 (2), (4) Date: Sep. 14, 2007 or 2 substituents; R is a substituted carbamoyl group; and R' (30) Foreign Application Priority Data is an optionally Substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the Feb. 9, 2005 (JP) .................................. O333562005 prophylaxis or treatment of GSK-3? related pathology or Dec. 22, 2005 (JP) .................................. 3709622005 disease, and a GSK-3? inhibitor including same. US 2009/0156582 A1 Jun.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]